COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #177 of 255
11/5 Late treatment study
Maldonado et al., NefrologĂ­a, doi:10.1016/j.nefro.2020.09.002 (Peer Reviewed)
COVID-19 incidence and outcomes in a home dialysis unit in Madrid (Spain) at the height of the pandemic
Source   PDF   Share   Tweet
Small retrospective 12 dialysis patients, 1/11 deaths with HCQ and 1/1 without HCQ.

Maldonado et al., 11/5/2020, retrospective, Spain, Europe, peer-reviewed, 10 authors.
risk of death, 90.9% lower, RR 0.09, p = 0.17, treatment 1 of 11 (9.1%), control 1 of 1 (100.0%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 255 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit